Nephroprotective impact of royal jelly against rhabdomyolysis-induced kidney damage in rats

Document Type : Original Article

Authors

1 Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s): The current work aimed at studying the impact of royal jelly on kidney damage caused by rhabdomyolysis in male rats.
Materials and Methods: 40 male rats were randomly assigned to five groups of eight: control, rhabdomyolysis, and rhabdomyolysis, administered with three doses of royal jelly (RJ) (100, 200, and 400 mg/kg) for seven days. On the fifth day, we injected glycerol intramuscularly to induce rhabdomyolysis. Researchers examined serum biochemical parameters, inflammation, oxidative stress, apoptosis, and kidney tissue injury.
Results: As a result of injecting glycerol, serum levels of creatinine, urea, and creatine phosphokinase were considerably elevated. The concentration of inflammatory mediators, as well as the expression of apoptotic parameters, was significantly elevated after glycerol injection. The percentage of kidney tissue damage and neutrophil gelatinase-associated lipocalin expression also increased significantly. Oral usage of RJ (100, 200, and 400 mg/kg) caused a decline in serum CPK, tissue level of total thiols, catalase activity, and renal expression of   BAX compared to the rhabdomyolysis group. Serum creatinine and NGAL expression were also significantly reduced by the RJ (200 and 400 mg/kg). RJ significantly reduced the concentration of inflammatory mediators at 100 and 200 mg/kg doses and the expression of bcl2 by RJ at 100 and 400 mg/kg doses.  
Conclusion: Royal jelly safeguards the kidney from rhabdomyolysis-related damage, primarily through its anti-oxidant, anti-apoptotic, and anti-inflammatory effects.

Keywords

Main Subjects

References

1. Stahl K, Rastelli E, Schoser B. A systematic review on the definition of Rhabdomyolysis. J Neurol 2020; 267: 877-882.
2. Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon 2020; 66: 101015.
3. Młynarska E, Krzemińska J, Wronka M, Franczyk B, Rysz J. Rhabdomyolysis-induced AKI (RIAKI) including the role of COVID-19. Int J Mol Sci 2022; 23: 8215-8230.
4. Nielsen FE, Cordtz JJ, Rasmussen TB, Christiansen CF. The association between rhabdomyolysis, acute kidney injury, renal replacement therapy, and mortality. Clin Epidemiol 2020; 12: 989-995.
5. Ahmad S, Anees M, Elahi I, Fazal-E-Mateen. Rhabdomyolysis leading to acute kidney injury. J Coll Physicians Surg Pak 2021; 31: 235-237.
6. Kwiatkowska M, Chomicka I, Malyszko J. Rhabdomyolysis - induced acute kidney injury - an underestimated problem. Wiad Lek 2020; 73: 2543-2548..
7. Safari S, Ghasemi M, Yousefifard M, Ghasemi A, Najafi I. Uric acid in predicting the traumatic rhabdomyolysis induced acute kidney injury: A systematic review and meta-analysis. BMC Nephrol 2024; 25: 82-89.
8. Ko A, Song J, Golovko G, El Ayadi A, Ozhathil DK, Wermine K, et al. Higher risk of acute kidney injury and death with rhabdomyolysis in severely burned patients. Surgery 2022; 171: 1412-1416. 
9. Zhu DC, Li WY, Zhang JW, Tong JS, Xie WY, Qin XL, et al. Rhabdomyolysis-associated acute kidney injury: clinical characteristics and intensive care unit transfer analysis. Intern Med J 2022; 52: 1251-1257.
10. Gupta A, Thorson P, Penmatsa KR, Gupta P. Rhabdomyolysis: Revisited. Ulster Med J 2021; 90: 61-69.
11. Petejova N, Martinek A. Acute kidney injury due to Rhabdomyolysis and renal replacement therapy: A critical review. Crit Care 2014; 18: 1-8.
12. Choy KH, McVeigh M, Holgate S, Delmonico L, Friedman ND. Rhabdomyolysis cases and acute kidneyinjury: A 10-year experience at a regional tertiary centre. Ren Soc Australasia J 2020; 16: 98-105.
13. Işıkkent A, Yılmaz S, Özturan İU, Doğan NÖ,Yaka E, Gültekin H, et al. Utility of neutrophil gelatinaseassociatedlipocalin in the management of acute kidneyinjury: A prospective, observational study. Hong Kong Med J 2020; 27: 8-14.
14. Helanova K, Spinar J, Parenica J. Diagnostic and prognostic utility of neutrophil gelatinase-associated lipocalin (NGAL) in patients with cardiovascular diseases--review. Kidney Blood Press Res 2014; 39: 623-629.
15. Boudhabhay I, Poillerat V, Grunenwald A, Torset C, Leon J, Daugan MV, et al. Complement activation is a crucial driver of acute kidney injury in Rhabdomyolysis. Kidney Int 2021; 99: 581-597.
16. Małek A, Strzemski M, Kurzepa J, Kurzepa J. Can bee venom be used as anticancer agent in modern medicine? Cancers 2023; 15: 3714-3730.
17. Mohamed HK, Mobasher MA, Ebiya RA, Hassen MT, Hagag HM, El-Sayed R, et al. Anti-inflammatory, anti-apoptotic, and anti-oxidant roles of honey, royal jelly, and propolis in suppressing nephrotoxicity induced by doxorubicin in male Albino rats. Antioxidants 2022; 11: 1029-1043.
18. Bagameri L, Baci GM, Dezmirean DS. Royal jelly as a nutraceutical natural product with a focus on its antibacterial activity. Pharmaceutics 2022; 14: 1142-1159.
19. Kanbur M, Eraslan G, Beyaz L, Silici S, Liman BC, Altinordulu S, et al. The effects of royal jelly on liver damage induced by paracetamol in mice. Exp Toxicol Pathol 2009; 61: 123-132.
20. Karadeniz A, Simsek N, Karakus E, Yildirim S, Kara A, Can I, et al. Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin. Oxid Med Cell Longev 2011; 2011: 981793-981802.
21. Singh AP, Junemann A, Muthuraman A, Jaggi AS, Singh N, Grover K, et al. Animal models of acute renal failure. Pharmacol Rep 2012; 64: 31-44.
22. Ghanbari E, Nejati V, Khazaei M. Anti-oxidant and protective effects of royal jelly on histopathological changes in testis of diabetic rats. Int J Reprod Biomed 2016; 14: 519-526.
23. Ahmed WM, Khalaf AA, Moselhy WA, Safwat GM. Royal jelly attenuates azathioprine induced toxicity in rats. Environ Toxicol Pharmacol 2014; 37: 431-437.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001; 25 : 402-408. 
25. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86: 271-278.
26. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25: 192-205.
27. Aebi H, Catalase In: Bergmeyer HU, Ed., Methods of Enzymatic Analysis, Verlag Chemie/Academic Press Inc., Weinheim/NewYork, 1974; 673-680.
28. Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: Role of iron in nephrotoxicity. Am J Physiol 1988; 255: F539-544.
29. Homsi E, Oliveira Dias EP, Garcia WE, Gontijo JA, Figueiredo JF. Effects of nifedipine and platelet activating factor antagonist (BN 52021) in glycerol-induced acute renal failure in rats. Ren Fail 1996; 18: 883-892.
30. Wang Y, Liu S, Liu Q, Lv Y. The interaction of central nervous system and acute kidney injury: Pathophysiology and clinical perspectives. Front Physiol 2022; 13: 826686-826694.
31. Grisk O. The sympathetic nervous system in acute kidney injury. Acta Physiol 2020; 228: e13404.
32. Nayak S, Jindal A. Myoglobinuria and acute kidney injury. J Integr Nephrol Androl 2015; 2: 50-54.
33. Kocot J, Kiełczykowska M, Luchowska-Kocot D, Kurzepa J, Musik I. Anti-oxidant potential of propolis, bee pollen, and royal jelly: Possible medical application. Oxid Med Cell Longev 2018; 2018: 7074209-7074209. 
34. Huang RS, Zhou JJ, Feng YY, Shi M, Guo F, Gou SJ, et al. Pharmacological inhibition of macrophage toll-like receptor 4/nuclear factor-kappa b alleviates rhabdomyolysis-induced acute kidney injury. Chin Med J 2017; 130: 2163-2169.
35. El-Seedi HR, Salama S, El-Wahed AAA, Guo Z, Di Minno A, Daglia M, et al. Exploring the therapeutic potential of royal jelly in metabolic disorders and gastrointestinal diseases. Nutrients 2024; 16: 393-409.
36. Yu X, Tu X, Tao L, Daddam J, Li S, Hu F. Royal jelly fatty acids: Chemical composition, extraction, biologicalactivity, and prospect. J Funct Foods 2023; 111: 105868.
37. Metwally Ibrahim SEL, Kosba AA. Royal jelly supplementation reduces skeletal muscle lipotoxicity and insulin resistance in aged obese rats. Pathophysiology 2018; 25: 307-315
38. Chen YF, Wang K, Zhang YZ, Zheng YF, Hu FL. In vitro anti-inflammatory effects of three fatty acids from royal jelly. Mediators Inflamm 2016; 2016: 3583684-3583694.
39. Yanagita M, Kojima Y, Mori K, Yamada S, Murakami S. Osteoinductive and anti-inflammatory effect of royal jelly on periodontal ligament cells. Biomed Res 2011; 32: 285-291.
40. Botezan S, Baci GM, Bagameri L, Pașca C, Dezmirean DS. Current status of the bioactive properties of royal jelly: a comprehensive review with a focus on its anticancer, anti-inflammatory, and antioxidant effects. Molecules 2023; 28: 1510-1533.
41. Gu H, Song I-B, Han H-J, Lee N-Y, Cha J-Y, SonY-K, et al. Anti-inflammatory and immune-enhancingeffects of enzyme-treated royal jelly. Appl Biol Chem 2018; 61: 227-233.
42. Kamogashira T, Fujimoto C, Yamasoba T. Reactive oxygen species, apoptosis, and mitochondrial dysfunction in hearing loss. Biomed Res Int 2015; 2015: 617207-617223.
43. Shang W, Wang Z. The update of NGAL in acute kidney injury. Curr Protein Pept Sci 2017; 18: 1211-1217.
44. Mårtensson J, Bellomo R. The rise and fall of NGAL in acute kidney injury. Blood Purif 2014; 37: 304-310.
45. Kümpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, Fliser D, et al. Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care 2010; 14: 1-9.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 5
May 2025
Pages 612-619

Files

Share

How to cite

Statistics